{"id":43845,"date":"2025-10-20T18:37:34","date_gmt":"2025-10-20T10:37:34","guid":{"rendered":"https:\/\/flcube.com\/?p=43845"},"modified":"2025-10-20T18:37:35","modified_gmt":"2025-10-20T10:37:35","slug":"novo-nordisk-secures-global-rights-to-zaltenibart-in-deal-with-omeros","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43845","title":{"rendered":"Novo Nordisk Secures Global Rights to Zaltenibart in Deal with Omeros"},"content":{"rendered":"\n<p><strong>Novo Nordisk<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVO:NYSE\">NYSE: NVO<\/a>) today announced the closing of a definitive asset purchase and license agreement with <strong>Omeros Corporation<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/OMER:NASDAQ\">NASDAQ: OMER<\/a>) for the candidate drug <strong>Zaltenibart<\/strong> (formerly OMS0906). Under the terms of the agreement, Novo will hold exclusive worldwide rights to develop, license, and commercialize Zaltenibart in all indications, while Omeros will receive up to <strong>USD\u202f2.1\u202fbillion<\/strong> in payments, including an upfront amount of <strong>USD\u202f340\u202fmillion<\/strong> and tiered royalties on net sales.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-highlights\">Deal Highlights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Exclusive Rights<\/strong><\/td><td>Novo\u202fNordisk gains global rights to Zaltenibart for all indications<\/td><\/tr><tr><td><strong>Financial Structure<\/strong><\/td><td>Up to USD\u202f2.1\u202fB: upfront + milestone + royalty payments<\/td><\/tr><tr><td><strong>Omeros Benefits<\/strong><\/td><td>USD\u202f340\u202fM upfront, additional development &amp; commercial milestones<\/td><\/tr><tr><td><strong>Pipeline Focus<\/strong><\/td><td>Rare blood &amp; kidney disorders; Phase\u202fII data for PNH in progress<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-zaltenibart-a-precision-complement-inhibitor\">Zaltenibart \u2013 A Precision Complement Inhibitor<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong> \u2013 Inhibits <strong>MASP\u20113<\/strong>, a key activator of the complement system\u2019s alternative pathway.<\/li>\n\n\n\n<li><strong>Mechanism<\/strong> \u2013 Antibody\u2011based blockade of MASP\u20113 reduces complement dysregulation implicated in rare diseases such as paroxysmal nocturnal hemoglobinuria (PNH).<\/li>\n\n\n\n<li><strong>Clinical Evidence<\/strong> \u2013 Positive Phase\u202fII data in PNH; ongoing studies aim to confirm efficacy and safety.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Novo\u202fNordisk\u2019s Expansion<\/strong> \u2013 Adds a high\u2011potential rare\u2011disease asset to its growing portfolio, positioning the company for global Phase\u202fIII testing in PNH and other indications.<\/li>\n\n\n\n<li><strong>Omeros\u2019 Monetization<\/strong> \u2013 Converts a proven biologic into a lucrative revenue stream while retaining rights to its broader MASP\u20113 small\u2011molecule pipeline.<\/li>\n\n\n\n<li><strong>Market Opportunity<\/strong> \u2013 Rare blood disorders represent an underserved therapeutic space with substantial unmet need and high pricing potential.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk (NYSE: NVO) today announced the closing of a definitive asset purchase and license&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43849,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4403,148,860,4402,24],"class_list":["post-43845","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-nasdaq-omer","tag-novo-nordisk","tag-nyse-nvo","tag-omeros","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk Secures Global Rights to Zaltenibart in Deal with Omeros - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk (NYSE: NVO) today announced the closing of a definitive asset purchase and license agreement with Omeros Corporation (NASDAQ: OMER) for the candidate drug Zaltenibart (formerly OMS0906). Under the terms of the agreement, Novo will hold exclusive worldwide rights to develop, license, and commercialize Zaltenibart in all indications, while Omeros will receive up to USD\u202f2.1\u202fbillion in payments, including an upfront amount of USD\u202f340\u202fmillion and tiered royalties on net sales.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43845\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk Secures Global Rights to Zaltenibart in Deal with Omeros\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk (NYSE: NVO) today announced the closing of a definitive asset purchase and license agreement with Omeros Corporation (NASDAQ: OMER) for the candidate drug Zaltenibart (formerly OMS0906). Under the terms of the agreement, Novo will hold exclusive worldwide rights to develop, license, and commercialize Zaltenibart in all indications, while Omeros will receive up to USD\u202f2.1\u202fbillion in payments, including an upfront amount of USD\u202f340\u202fmillion and tiered royalties on net sales.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43845\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-20T10:37:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-20T10:37:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2002.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43845#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43845\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk Secures Global Rights to Zaltenibart in Deal with Omeros\",\"datePublished\":\"2025-10-20T10:37:34+00:00\",\"dateModified\":\"2025-10-20T10:37:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43845\"},\"wordCount\":278,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43845#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2002.webp\",\"keywords\":[\"NASDAQ: OMER\",\"Novo Nordisk\",\"NYSE: NVO\",\"Omeros\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43845#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43845\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43845\",\"name\":\"Novo Nordisk Secures Global Rights to Zaltenibart in Deal with Omeros - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43845#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43845#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2002.webp\",\"datePublished\":\"2025-10-20T10:37:34+00:00\",\"dateModified\":\"2025-10-20T10:37:35+00:00\",\"description\":\"Novo Nordisk (NYSE: NVO) today announced the closing of a definitive asset purchase and license agreement with Omeros Corporation (NASDAQ: OMER) for the candidate drug Zaltenibart (formerly OMS0906). Under the terms of the agreement, Novo will hold exclusive worldwide rights to develop, license, and commercialize Zaltenibart in all indications, while Omeros will receive up to USD\u202f2.1\u202fbillion in payments, including an upfront amount of USD\u202f340\u202fmillion and tiered royalties on net sales.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43845#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43845\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43845#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2002.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/2002.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk Secures Global Rights to Zaltenibart in Deal with Omeros\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43845#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk Secures Global Rights to Zaltenibart in Deal with Omeros\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk Secures Global Rights to Zaltenibart in Deal with Omeros - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk (NYSE: NVO) today announced the closing of a definitive asset purchase and license agreement with Omeros Corporation (NASDAQ: OMER) for the candidate drug Zaltenibart (formerly OMS0906). Under the terms of the agreement, Novo will hold exclusive worldwide rights to develop, license, and commercialize Zaltenibart in all indications, while Omeros will receive up to USD\u202f2.1\u202fbillion in payments, including an upfront amount of USD\u202f340\u202fmillion and tiered royalties on net sales.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43845","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk Secures Global Rights to Zaltenibart in Deal with Omeros","og_description":"Novo Nordisk (NYSE: NVO) today announced the closing of a definitive asset purchase and license agreement with Omeros Corporation (NASDAQ: OMER) for the candidate drug Zaltenibart (formerly OMS0906). Under the terms of the agreement, Novo will hold exclusive worldwide rights to develop, license, and commercialize Zaltenibart in all indications, while Omeros will receive up to USD\u202f2.1\u202fbillion in payments, including an upfront amount of USD\u202f340\u202fmillion and tiered royalties on net sales.","og_url":"https:\/\/flcube.com\/?p=43845","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-20T10:37:34+00:00","article_modified_time":"2025-10-20T10:37:35+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2002.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43845#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43845"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk Secures Global Rights to Zaltenibart in Deal with Omeros","datePublished":"2025-10-20T10:37:34+00:00","dateModified":"2025-10-20T10:37:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43845"},"wordCount":278,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43845#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2002.webp","keywords":["NASDAQ: OMER","Novo Nordisk","NYSE: NVO","Omeros","Rare \/ orphan disease drugs"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43845#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43845","url":"https:\/\/flcube.com\/?p=43845","name":"Novo Nordisk Secures Global Rights to Zaltenibart in Deal with Omeros - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43845#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43845#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2002.webp","datePublished":"2025-10-20T10:37:34+00:00","dateModified":"2025-10-20T10:37:35+00:00","description":"Novo Nordisk (NYSE: NVO) today announced the closing of a definitive asset purchase and license agreement with Omeros Corporation (NASDAQ: OMER) for the candidate drug Zaltenibart (formerly OMS0906). Under the terms of the agreement, Novo will hold exclusive worldwide rights to develop, license, and commercialize Zaltenibart in all indications, while Omeros will receive up to USD\u202f2.1\u202fbillion in payments, including an upfront amount of USD\u202f340\u202fmillion and tiered royalties on net sales.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43845#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43845"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43845#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2002.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2002.webp","width":1080,"height":608,"caption":"Novo Nordisk Secures Global Rights to Zaltenibart in Deal with Omeros"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43845#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk Secures Global Rights to Zaltenibart in Deal with Omeros"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2002.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43845","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43845"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43845\/revisions"}],"predecessor-version":[{"id":43850,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43845\/revisions\/43850"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43849"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43845"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43845"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43845"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}